# A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation

> **NCT05473910** · PHASE1 · RECRUITING · sponsor: **TScan Therapeutics, Inc.** · enrollment: 75 (estimated)

## Conditions studied

- AML
- Myelodysplastic Syndromes
- ALL, Adult

## Interventions

- **DRUG:** SOC + TSC-100
- **DRUG:** SOC + TSC-101
- **OTHER:** Control

## Key facts

- **NCT ID:** NCT05473910
- **Lead sponsor:** TScan Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05473910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05473910, "A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05473910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*